Disease · MONDO_0005347
Comparisons in its trials17
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 17 of 17
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Omega-3 Pentaenoic Acid (MAT9001) vs Icosapent Ethyl (Vascepa): deaths from any cause | 0 of 97 | 0 of 100 | 197 | NCT04177680 | Trial comparisons |
| Omega-3 Pentaenoic Acid (MAT9001) vs Icosapent Ethyl (Vascepa): serious adverse events | 0 of 97 | 0 of 100 | 197 | NCT04177680 | Trial comparisons |
| Epanova vs Olive Oil: serious adverse events | 1 of 81 | 2 of 81 | 162 | NCT02009865 | Trial comparisons |
| Volanesorsen Total vs Placebo: Treatment Response Rate Defined as Participants With Fasting TG ≥ 40% Reduction From Baseline at Month 3 | 65 of 75 | 5 of 38 | 113 | NCT02300233 | Trial comparisons |
| Volanesorsen Total vs Placebo: Treatment Response Rate Defined as Participants With Fasting TG < 150 mg/dL Reduction From Baseline at Month 3 | 11 of 75 | 0 of 38 | 113 | NCT02300233 | Trial comparisons |
| Pegozafermin vs Placebo: Number of Participants Who Achieved TG <500 mg/dL at Week 8 | 51 of 64 | 5 of 17 | 81 | NCT04541186 | Trial comparisons |
| Intervention vs Control: serious adverse events | 0 of 25 | 0 of 29 | 54 | NCT01280604 | Trial comparisons |
| POM3 vs Placebo: serious adverse events | 0 of 23 | 0 of 23 | 46 | NCT01034540 | Trial comparisons |
| Lovaza vs Placebo: serious adverse events | 0 of 12 | 0 of 12 | 24 | NCT00672633 | Trial comparisons |
| Arm 2 Combined Cohort A + B: REGN4461 to REGN4461 vs Arm 1 Combined Cohort A + B: Placebo to REGN4461: Number of Participants With Treatment-emergent Anti-drug Antibody (ADA) Response | 0 of 10 | 0 of 10 | 20 | NCT05088460 | Trial comparisons |
| Human Recombinant Leptin (Metreleptin) vs Placebo Injection: serious adverse events | 2 of 9 | 1 of 8 | 17 | NCT01511016 | Trial comparisons |
| Fish Oil Supplementation (Group A) vs Placebo Supplementation (Group B): Participants With Normalized Liver Enzyme Levels | 0 of 4 | 0 of 4 | 8 | NCT01285362 | Trial comparisons |
| Fish Oil Supplementation (Group A) vs Placebo Supplementation (Group B): deaths from any cause | 0 of 4 | 0 of 4 | 8 | NCT01285362 | Trial comparisons |
| Fish Oil Supplementation (Group A) vs Placebo Supplementation (Group B): serious adverse events | 0 of 4 | 0 of 4 | 8 | NCT01285362 | Trial comparisons |
| Fish Oil Supplementation (Group A) vs Placebo Supplementation (Group B): Number of Participants With Normalization of Plasma Lipid Levels | 0 of 3 | 0 of 3 | 6 | NCT01285362 | Trial comparisons |
| Group 1: 300 mg Gemcabene Daily Week 1-24 vs Group 2: 600mg Gemcabene Daily Week 12-24: deaths from any cause | 0 of 2 | 0 of 3 | 5 | NCT03508687 | Trial comparisons |
| Group 1: 300 mg Gemcabene Daily Week 1-24 vs Group 2: 600mg Gemcabene Daily Week 12-24: serious adverse events | 0 of 2 | 1 of 3 | 5 | NCT03508687 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005347/comparisons